Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD01 in Anemia of Chronic Renal Failure
NCT04231292Phase 2Unknown
- Sponsor
- Shenzhen Sciprogen Bio-Pharmaceutical Co., Ltd.
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of pegerthropoietin in anemia of chronic kidney disease (CKD-A) (7 arms), sponsored by Shenzhen Sciprogen Bio-Pharmaceutical Co., Ltd. Primary endpoints: Change of hemoglobin concentration from baseline and Difference of hemoglobin concentration between the experimental group and the placebo group at 6 weeks. Status: unknown.
02
Drugs
pegerthropoietin
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04231292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231292.